



## DEPARTMENT OF HEALTH & HUMAN SERVICES

---

Food and Drug Administration  
Rockville, MD 20857

February 27, 2020

Alina Garbar, PhD  
RA Director  
Aurora Pharmaceutical, Inc.  
1196 Hwy 3 South  
Northfield, MN 55057

Sent via email to: [agarbar@aurorapharmaceutical.com](mailto:agarbar@aurorapharmaceutical.com)

Dear Petitioner:

Your petition to the Commissioner of Food and Drug Administration requesting an FDA permission to file an abbreviated new animal drug application for generic animal drug Deracoxib Solution 1.80% w/v, that differs from the reference listed drug Deramaxx™ (deracoxib) Chewable Tablets, sponsored by Elanco US Inc. under NADA 141-203, in dosage form and strength was received by this office on 02/27/2020.

It has been assigned docket number FDA-2020-P-0963. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Karen Malvin  
Supervisory Administrative Proceedings Officer  
Dockets Management Staff  
FDA/Office of Operations (OO)